Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix (NASDAQ: QTRX) announced that on January 15, 2026 it granted inducement awards to four new employees under its 2025 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4). The grants comprise 88,050 RSUs and options to purchase an aggregate of 125,745 shares at an exercise price of $7.95 per share (the closing price on the grant date). RSUs and options vest 25% after one year, then monthly over 36 months; options have a 10-year term. Awards were approved by the Compensation Committee.
Quanterix (NASDAQ: QTRX) highlighted a Nature study using its Simoa p-Tau 217 assay on a Norwegian cohort of 11,000+ individuals aged 58+. The study reports age-stratified Alzheimer’s Disease Neuropathological Changes (ADNC) rising from 10% at 58–69.9 to 64.9% in those >90, and finds 30.4% ADNC in people aged 70+, with 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. Researchers state ~10% of the 70+ population meet current treatment eligibility. Results used a validated commercial p-Tau 217 kit on an automated HD-X analyzer, aiming to improve population-level prevalence estimates and planning for therapies and trials.
Quanterix (NASDAQ: QTRX) announced publication in the journal Brain of a landmark study showing a dual-biomarker blood-test approach for multiple sclerosis (MS). The research found serum GFAP levels were significantly associated with higher risk of Progression Independent of Relapse Activity (PIRA), while serum NfL continued to predict future relapses and acute inflammatory activity. The study used the automated HD-X and the Simoa Neurology 2-Plex B kit and leveraged large Simoa-derived normative databases from thousands of individuals. An online interpretive tool adjusts for age, sex, and BMI to enable individualized clinical interpretation and monitoring.
Quanterix (NASDAQ: QTRX) reported third-quarter 2025 results for the period ending September 30, 2025, with revenue of $40.2M, up 12.3% year-over-year, and GAAP gross margin 42.8% (adjusted gross margin 45.9%).
The company highlighted post‑Akoya integration progress, capturing $67M of cost synergies and projecting $85M annualized synergies and cash‑flow breakeven in 2026. Adjusted EBITDA loss was $11.9M; cash and equivalents totaled $138.1M with expected year‑end cash of ~$120M. 2025 revenue guidance reiterated at $130–$135M (pro forma $165–$170M); adjusted cash use expected $34–$38M.
Quanterix (NASDAQ: QTRX) will report third quarter 2025 financial results and host a conference call on Monday, November 10, 2025 at 4:30 p.m. ET. The company will release a press release with its Q3 2025 results after market close on November 10, 2025, posted on its website.
Investors can join the live call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 3186071, or listen via live webcast on the Quanterix Investors News & Events page. An archived replay will be available on the company website for one year.
Quanterix (NASDAQ: QTRX) has achieved a significant milestone as its Accelerator Laboratory received a clinical laboratory permit from the New York State Department of Health (NYSDOH) in the Clinical Chemistry category. The lab is now CLIA-certified across all 50 states, enabling nationwide clinical testing and biomarker analysis.
The state-of-the-art facility utilizes Simoa® technology for ultra-sensitive protein biomarker detection and has developed over 100 custom assays, supporting 264+ global clinical trials across neurology, immunology/oncology, and infectious diseases. The lab's Simoa® NfL Laboratory Developed Test (LDT) received approval as part of the permitting process.
Additionally, the company announced the integration of Lucent Diagnostics brand under the Accelerator Laboratory, expanding its clinical and research biomarker testing capabilities.
Quanterix (NASDAQ: QTRX), a biomarker detection technology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Tuesday, August 12th, at 3:30 p.m. ET in Boston, Massachusetts.
The company's executive team will conduct the presentation and hold one-on-one meetings with institutional investors. Interested parties can access the live webcast through the Investors section of Quanterix's website, with a replay available for a limited time after the event.
Quanterix (NASDAQ: QTRX) reported Q2 2025 financial results, highlighting its recent acquisition of Akoya Biosciences. The company posted revenue of $24.5 million, down 29% year-over-year, with a GAAP gross margin of 46.2%. The quarter resulted in a net loss of $30.0 million.
Key developments include achieving 75% of their $85 million synergy and cost reduction target, launching new p-Tau assays for Alzheimer's research, and obtaining medical device registration approval in China. The company maintains $263.8 million in cash and equivalents, with adjusted cash usage of $2.6 million.
For full-year 2025, Quanterix expects revenues of $130-135 million, or $165-170 million on a pro forma basis including Akoya. The company projects achieving cash flow breakeven in 2026.
Quanterix (NASDAQ: QTRX), a biomarker detection technology company, has scheduled its second quarter 2025 financial results conference call for Thursday, August 7, 2025, at 4:30 p.m. ET. The company will release its Q2 2025 financial results after market close on the same day.
Investors can access the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5591565. A live webcast will be available on the company's website, with an archived replay accessible for one year.
Quanterix (NASDAQ: QTRX), a biomarker detection company, has announced a cooperation agreement with Kent Lake Capital. The key terms include: appointment of a new independent director by December 1, 2025, through a joint search process involving both parties, plans to declassify the Board at the 2025 Annual Meeting, and adoption of a majority voting standard for uncontested director elections.
Kent Lake has agreed to withdraw its director nominations and support the Board's candidates, along with accepting standstill and voting commitments until 30 days before Quanterix's 2027 Annual Meeting nomination deadline. The agreement aims to maintain focus on company strategy and maximize benefits from the Akoya transaction.